These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 22752425

  • 1. Killing of Kras-mutant colon cancer cells via Rac-independent actin remodeling by the βGBP cytokine, a physiological PI3K inhibitor therapeutically effective in vivo.
    Mallucci L, Shi DY, Davies D, Jordan P, Nicol A, Lotti L, Mariani-Costantini R, Verginelli F, Wells V, Zicha D.
    Mol Cancer Ther; 2012 Sep; 11(9):1884-93. PubMed ID: 22752425
    [Abstract] [Full Text] [Related]

  • 2. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
    Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N.
    Cancer Res; 2010 Sep 01; 70(17):6804-14. PubMed ID: 20699365
    [Abstract] [Full Text] [Related]

  • 3. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
    Chen J, Bi H, Hou J, Zhang X, Zhang C, Yue L, Wen X, Liu D, Shi H, Yuan J, Liu J, Liu B.
    Cell Death Dis; 2013 Sep 26; 4(9):e814. PubMed ID: 24071646
    [Abstract] [Full Text] [Related]

  • 4. Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.
    Wells V, Mallucci L.
    Breast Cancer Res; 2009 Sep 26; 11(1):R2. PubMed ID: 19133120
    [Abstract] [Full Text] [Related]

  • 5. The end of KRAS, and other, cancers? A new way forward.
    Mallucci L, Wells V.
    Drug Discov Today; 2014 Apr 26; 19(4):383-7. PubMed ID: 24291216
    [Abstract] [Full Text] [Related]

  • 6. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
    Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J.
    Clin Cancer Res; 2013 Jul 01; 19(13):3533-44. PubMed ID: 23674493
    [Abstract] [Full Text] [Related]

  • 7. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
    Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA.
    J Clin Invest; 2011 Nov 01; 121(11):4311-21. PubMed ID: 21985784
    [Abstract] [Full Text] [Related]

  • 8. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.
    Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP, Rosen DM, Denmeade SR, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, Croessmann S, Cochran RL, Karnan S, Konishi Y, Ota A, Hosokawa Y, Argani P, Lauring J, Park BH.
    Cancer Res; 2013 Jun 01; 73(11):3248-61. PubMed ID: 23580570
    [Abstract] [Full Text] [Related]

  • 9. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
    Hong S, Kim S, Kim HY, Kang M, Jang HH, Lee WS.
    Cancer Med; 2016 Feb 01; 5(2):248-55. PubMed ID: 26715098
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
    Gulhati P, Zaytseva YY, Valentino JD, Stevens PD, Kim JT, Sasazuki T, Shirasawa S, Lee EY, Weiss HL, Dong J, Gao T, Evers BM.
    Carcinogenesis; 2012 Sep 01; 33(9):1782-90. PubMed ID: 22696593
    [Abstract] [Full Text] [Related]

  • 11. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
    Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R.
    PLoS One; 2012 Sep 01; 7(5):e38033. PubMed ID: 22675430
    [Abstract] [Full Text] [Related]

  • 12. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
    Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS.
    Oncogene; 2014 Mar 20; 33(12):1590-600. PubMed ID: 23542178
    [Abstract] [Full Text] [Related]

  • 13. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
    Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M, Roberts TM, Sellers WR, Hofmann F, Maira SM.
    PLoS One; 2012 Mar 20; 7(8):e44146. PubMed ID: 22952903
    [Abstract] [Full Text] [Related]

  • 14. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
    Haagensen EJ, Thomas HD, Mudd C, Tsonou E, Wiggins CM, Maxwell RJ, Moore JD, Newell DR.
    Eur J Cancer; 2016 Mar 20; 56():69-76. PubMed ID: 26820797
    [Abstract] [Full Text] [Related]

  • 15. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J.
    BMC Med Genomics; 2010 Jun 30; 3():26. PubMed ID: 20591134
    [Abstract] [Full Text] [Related]

  • 16. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.
    Oncogene; 2011 Feb 03; 30(5):561-74. PubMed ID: 20956938
    [Abstract] [Full Text] [Related]

  • 17. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
    Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A.
    J Clin Invest; 2010 Aug 03; 120(8):2858-66. PubMed ID: 20664172
    [Abstract] [Full Text] [Related]

  • 18. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J, Zheng B, Ji J, Shen F, Min H, Liu B, Wu J, Zhang S.
    Tumour Biol; 2015 May 03; 36(5):3301-8. PubMed ID: 25524577
    [Abstract] [Full Text] [Related]

  • 19. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A.
    Int J Cancer; 2014 Jun 01; 134(11):2560-71. PubMed ID: 24374738
    [Abstract] [Full Text] [Related]

  • 20. PIK3CA mutations in advanced cancers: characteristics and outcomes.
    Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R.
    Oncotarget; 2012 Dec 01; 3(12):1566-75. PubMed ID: 23248156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.